The ambitious and ambitious startup Rubius Therapeutics recently put together three pillars of a successful project. This is the money of large investors in the amount of $ 120 million, a team of scientists, doctors and managers, plus about $ 100 million in donations from interested first clients. The result should be a technology for creating "superblood" - an almost universal means of treating many diseases.
The concept of superblood is based on the existing method of using T-lymphocytes to enhance the immune response of the human body. If, instead of a lymphocyte, we take an erythrocyte and add a highly specialized protein to it, and then introduce these modified cells into a person's blood, he will receive a cure for a specific disease. For example, it can compensate for the lack of certain enzymes and cure lupus, type 1 diabetes, or some forms of cancer.
There are three advantages to "superblood". Firstly, it allows you to do only with biological agents, without the use of harmful chemicals or synthetics. Secondly, less than 1% of the patient's blood needs to be replaced for treatment and his body will not receive any other effect than the programmed one. Thirdly, to generate a drug, one donor with the first blood group and Rh negative is enough, from whose biomaterial thousands of doses can be made for different people.
There is exactly one disadvantage of the "superblood" technology: it does not exist yet. Rubius Therapeutics startup was created with the aim of developing the concept and creating the first real samples of the substance, as well as conducting research that will prove or disprove the feasibility of this type of treatment.